CARISMA THERAPEUTICS INC (CARM) Stock Price, Forecast & Analysis
USA - NASDAQ:CARM - US14216R1014 - Common Stock
CARM Key Statistics, Chart & Performance
The current stock price of CARM is 0.1539 USD. In the past month the price decreased by -58.86%. In the past year, price decreased by -83.48%.
CARM Latest News, Press Relases and Analysis
CARM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 386.95B | ||
| AMGN | AMGEN INC | 14.43 | 169.90B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.37 | 68.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.71 | 57.74B | ||
| ARGX | ARGENX SE - ADR | 63.46 | 52.40B | ||
| INSM | INSMED INC | N/A | 39.25B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.37 | 36.51B | ||
| NTRA | NATERA INC | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.85B | ||
| BIIB | BIOGEN INC | 9.36 | 22.98B |
Related stock screener links
About CARM
Company Profile
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Philadelphia, Pennsylvania and currently employs 46 full-time employees. The company went IPO on 2014-02-06. The firm seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. The company is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.
Company Info
CARISMA THERAPEUTICS INC
3675 Market Street, Suite 401
PHILADELPHIA PENNSYLVANIA US
Employees: 46
Phone: 12674916422
CARISMA THERAPEUTICS INC / CARM FAQ
Can you describe the business of CARISMA THERAPEUTICS INC?
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Philadelphia, Pennsylvania and currently employs 46 full-time employees. The company went IPO on 2014-02-06. The firm seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. The company is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.
Can you provide the latest stock price for CARISMA THERAPEUTICS INC?
The current stock price of CARM is 0.1539 USD. The price decreased by -43.81% in the last trading session.
What is the dividend status of CARISMA THERAPEUTICS INC?
CARM does not pay a dividend.
What is the ChartMill rating of CARISMA THERAPEUTICS INC stock?
CARM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the analyst forecast for CARM stock?
8 analysts have analysed CARM and the average price target is 1.02 USD. This implies a price increase of 562.77% is expected in the next year compared to the current price of 0.1539.
Can you provide the PE ratio for CARM stock?
CARISMA THERAPEUTICS INC (CARM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.18).
When is the next dividend date for CARISMA THERAPEUTICS INC (CARM)?
The next ex-dividend date for CARISMA THERAPEUTICS INC (CARM) is March 8, 2023.
CARM Technical Analysis
CARM Financial Highlights
Over the last trailing twelve months CARM reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 33.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -985.18% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CARM Forecast & Estimates
8 analysts have analysed CARM and the average price target is 1.02 USD. This implies a price increase of 562.77% is expected in the next year compared to the current price of 0.1539.
For the next year, analysts expect an EPS growth of 45.16% and a revenue growth -100% for CARM